PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 6433985-7 1984 The results of these studies show that the action of lysophosphatidic acid on platelets differs from the action of thrombin, U46619 and platelet-activating factor, which produce a rapid rise in [32P]phosphatidic acid, and suggests that lysophosphatidic acid, like A23187, largely bypasses the initial receptor-coupled breakdown of phosphoinositides leading to formation of diacylglycerols and phosphatidic acid. lysophosphatidic acid 236-257 coagulation factor II, thrombin Homo sapiens 115-123 3931692-3 1985 In the present study, mepacrine was used at a concentration of 2.5-20 microM, sufficient to block aggregation and lysophosphatidic acid formation induced by 0.1 U/ml thrombin. lysophosphatidic acid 114-135 coagulation factor II, thrombin Homo sapiens 166-174 3931692-5 1985 However, mepacrine also partly inhibited the formation of phosphatidic acid in response to thrombin, consistent with some simultaneous inhibition of phospholipase C. Lysophosphatidic acid (2.5-22 microM) overcame the mepacrine block in thrombin-stimulated aggregation, protein phosphorylation and secretion without stimulating the release of arachidonic acid from platelet phospholipids or the formation of lysophosphatidic acid, and only slightly increasing phosphatidic acid formation. lysophosphatidic acid 166-187 coagulation factor II, thrombin Homo sapiens 236-244 3931692-6 1985 The results suggest that lysophosphatidic acid primarily acts distal to mepacrine inhibition of phospholipase A2 and phospholipase C and are consistent with the possibility that lysophosphatidic acid might be a mediator of part of the effects of low-dose thrombin on human platelets. lysophosphatidic acid 25-46 coagulation factor II, thrombin Homo sapiens 255-263 3931692-6 1985 The results suggest that lysophosphatidic acid primarily acts distal to mepacrine inhibition of phospholipase A2 and phospholipase C and are consistent with the possibility that lysophosphatidic acid might be a mediator of part of the effects of low-dose thrombin on human platelets. lysophosphatidic acid 178-199 coagulation factor II, thrombin Homo sapiens 255-263 3853461-6 1985 A concentration of thrombin (0.2 unit/ml), which produced maximal platelet aggregation, caused an estimated intracellular formation of 20 microM-lysophosphatidic acid in the presence of 2 mM-Ca2+; however, there was no detectable release of lysophosphatidic acid into the bathing medium. lysophosphatidic acid 145-166 coagulation factor II, thrombin Homo sapiens 19-27 3853461-6 1985 A concentration of thrombin (0.2 unit/ml), which produced maximal platelet aggregation, caused an estimated intracellular formation of 20 microM-lysophosphatidic acid in the presence of 2 mM-Ca2+; however, there was no detectable release of lysophosphatidic acid into the bathing medium. lysophosphatidic acid 241-262 coagulation factor II, thrombin Homo sapiens 19-27 3931692-0 1985 Mepacrine (quinacrine) inhibition of thrombin-induced platelet responses can be overcome by lysophosphatidic acid. lysophosphatidic acid 92-113 coagulation factor II, thrombin Homo sapiens 37-45 3931692-1 1985 Addition of thrombin to human platelets results in production of lysophosphatidic acid. lysophosphatidic acid 65-86 coagulation factor II, thrombin Homo sapiens 12-20 6795196-0 1981 Lysophosphatidic acid potentiates the thrombin-induced production of arachidonate metabolites in platelets. lysophosphatidic acid 0-21 coagulation factor II, thrombin Homo sapiens 38-46 6795196-1 1981 Concentrations (1 to 20 microM) of 1-oleoyl-lysophosphatidic acid which alone do not affect platelet metabolism of arachidonic acid, do augment the effects of suboptimal concentrations of thrombin on the formation of [14C]phosphatidic acid and the production of [14C]arachidonate metabolites from platelets prelabeled with [14C]arachidonate. lysophosphatidic acid 35-65 coagulation factor II, thrombin Homo sapiens 188-196 17110600-9 2007 Furthermore, LPA-exposed erythrocytes actually potentiated the thrombin generation as determined by prothrombinase assay and accelerated the coagulation process initiated by recombinant human tissue factor in plasma. lysophosphatidic acid 13-16 coagulation factor II, thrombin Homo sapiens 63-71 214164-0 1978 Phosphatidic and lysophosphatidic acid production in phospholipase C-and thrombin-treated platelets. lysophosphatidic acid 17-38 coagulation factor II, thrombin Homo sapiens 73-81 32222693-7 2020 Further, LPA-treated erythrocytes triggered thrombin generation in platelet-free plasma which was partially impaired in the presence of TA and EGCG. lysophosphatidic acid 9-12 coagulation factor II, thrombin Homo sapiens 44-52 21832043-8 2011 ATX increases thrombin-stimulated LPA production by washed platelets ~10-fold. lysophosphatidic acid 34-37 coagulation factor II, thrombin Homo sapiens 14-22 15447683-8 2004 Thrombin and LPA receptors also differentially activated Gq pathways as thrombin but not LPA increased InsP3 formation and reduced phosphatidylinositol 4,5-bisphosphate (PIP2) levels. lysophosphatidic acid 13-16 coagulation factor II, thrombin Homo sapiens 72-80 12594220-3 2003 For example, thrombin and lysophosphatidic acid (LPA) have been shown to induce stress fiber formation via Galpha(12) and Galpha(13), respectively. lysophosphatidic acid 49-52 coagulation factor II, thrombin Homo sapiens 13-21 9453463-4 1997 Migration induced by either LPA or thrombin was inhibited by the actin cytoskeleton-disrupting agent, cytochalasin B, by the Rho protein-inactivating Clostridium difficile toxin B, by preventing [Ca2+]i transients with an intracellular calcium-chelating agent, and by the phorbol ester, phorbol 12-myristate 13-acetate, which also blocked the LPA- and thrombin-induced [Ca2+]i increases. lysophosphatidic acid 343-346 coagulation factor II, thrombin Homo sapiens 35-43 10622253-2 1999 The transactivation of epidermal growth factor receptor (EGFR)-dependent signalling pathways upon stimulation of G-protein-coupled receptors (GPCRs), which are critical for the mitogenic activity of ligands such as lysophosphatidic acid, endothelin, thrombin, bombesin and carbachol, provides evidence for such an interconnected communication network. lysophosphatidic acid 215-236 coagulation factor II, thrombin Homo sapiens 250-258 9553056-2 1998 This cytoskeletal response is rapid, peaking 2 h after thrombin stimulation, and reverses by 50% after 24 h. The thrombin receptor peptide SFLLRNP also induces cell rounding, whereas other G protein-linked receptor agonists such as carbachol, lysophosphatidic acid, or bradykinin fail to do so. lysophosphatidic acid 243-264 coagulation factor II, thrombin Homo sapiens 113-121 9453463-4 1997 Migration induced by either LPA or thrombin was inhibited by the actin cytoskeleton-disrupting agent, cytochalasin B, by the Rho protein-inactivating Clostridium difficile toxin B, by preventing [Ca2+]i transients with an intracellular calcium-chelating agent, and by the phorbol ester, phorbol 12-myristate 13-acetate, which also blocked the LPA- and thrombin-induced [Ca2+]i increases. lysophosphatidic acid 28-31 coagulation factor II, thrombin Homo sapiens 352-360 8004064-7 1994 These results indicate that lysophosphatidic acid production by thrombin-activated platelets could play a significant role in the regulation of the inflammatory response. lysophosphatidic acid 28-49 coagulation factor II, thrombin Homo sapiens 64-72 8192895-0 1993 Increased phosphatidic acid and decreased lysophosphatidic acid in response to thrombin is associated with inhibition of platelet aggregation. lysophosphatidic acid 42-63 coagulation factor II, thrombin Homo sapiens 79-87